Australia markets closed

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.1600-0.0300 (-0.72%)
At close: 04:00PM EDT
3.9600 -0.20 (-4.81%)
After hours: 06:31PM EDT

MacroGenics, Inc.

9704 Medical Center Drive
Rockville, MD 20850
United States
301 251 5172
https://www.macrogenics.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 427

Key executives

NameTitlePayExercisedYear born
Dr. Scott Koenig M.D., Ph.D.Pres, CEO & Director954.14kN/A1952
Mr. James KarrelsSr. VP, CFO & Corp. Sec.577.9k115.53k1967
Mr. Eric Blasius RisserChief Operating Officer571.98kN/A1973
Dr. Ezio BonviniSr. VP of Research & Chief Scientific Officer612.21k264.03k1954
Dr. Thomas M. Spitznagel Ph.D.Sr. VP of Technical Operations550.97k204.5k1967
Dr. Christopher Shayne James M.D.VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Jeffrey Stuart PetersSr. VP & Gen. CounselN/AN/A1972
Dr. Stephen L. EckSr. VP of Clinical Devel. & Chief Medical OfficerN/AN/A1955
Ms. Lynn CilinskiVP, Controller & TreasurerN/AN/A1958
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 Γ— CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Γ— CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Corporate governance

MacroGenics, Inc.’s ISS governance QualityScore as of 1 May 2022 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.